{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"86"},{"groupId":"OG002","value":"93"},{"groupId":"OG003","value":"85"}]}],"title":"6 Months (n=43,44,44,41)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"89"},{"groupId":"OG002","value":"93"},{"groupId":"OG003","value":"86"}]}],"title":"24 Months (n=43,44,44,42)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"42"}],"units":"Participants"}],"description":"A CHR was obtained when all the following criteria were met: White Blood Cells (WBC) ≤ institutional upper limit of normal (ULN); Platelets \\< 450,000/mm³; No blasts or promyelocytes in peripheral blood (PB); \\< 5% myelocytes plus metamyelocytes in PB; Basophils in PB \\< 20%; No extramedullary involvement (including no splenomegaly or hepatomegaly). Hematologic responses were counted anytime following 14 days after the dosing start date.","groups":[{"description":"Participants received 100 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.\n\nAfter the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG000","title":"Dasatinib 100 mg QD"},{"description":"Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG001","title":"Dasatinib 140 mg QD"},{"description":"Participants received 50 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG002","title":"Dasatinib 50 mg BID"},{"description":"Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG003","title":"Dasatinib 70 mg BID"}],"paramType":"NUMBER","populationDescription":"All randomized imatinib-intolerant participants were summarized.","reportingStatus":"POSTED","timeFrame":"6 months, 24 months","title":"Percent of Participants Intolerant to Imatinib With CHR at 6 Months and at 24 Months Follow-Up","type":"SECONDARY","unitOfMeasure":"percentage of participants"}